Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early

BackgroundGlioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain the primary therapeutic options for GB, and no new therapies have been introduced in recent years. This therapeutic stand...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mariangela Morelli, Francesca Lessi, Serena Barachini, Romano Liotti, Nicola Montemurro, Paolo Perrini, Orazio Santo Santonocito, Carlo Gambacciani, Matija Snuderl, Francesco Pieri, Filippo Aquila, Azzurra Farnesi, Antonio Giuseppe Naccarato, Paolo Viacava, Francesco Cardarelli, Gianmarco Ferri, Paul Mulholland, Diego Ottaviani, Fabiola Paiar, Gaetano Liberti, Francesco Pasqualetti, Michele Menicagli, Paolo Aretini, Giovanni Signore, Sara Franceschi, Chiara Maria Mazzanti
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-09-01
Saila:	Frontiers in Oncology
Gaiak:	glioblastoma metabolic imaging drug response assay predictive model FLIM (fluorescence lifetime imaging microscopy)
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2022.969812/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!